TRK Inhibitor Active in Treatment-Refractory Glioblastoma

(MedPage Today) -- HOUSTON -- A fourth of patients with TRK fusion primary central nervous system tumors responded to the TRK inhibitor larotrectinib (Vitrakvi), including almost 40% of pediatric patients, pooled data from two studies showed...